Literature DB >> 35644057

Delta-8 THC use in US adults: Sociodemographic characteristics and correlates.

Ofir Livne1, Alan Budney2, Jacob Borodovsky2, Claire Walsh3, Dvora Shmulewitz4, David S Fink3, Cara A Struble2, Mohammad Habib2, Efrat Aharonovich4, Deborah S Hasin5.   

Abstract

BACKGROUND: Use of novel cannabis products whose primary active compound is Delta-8 tetrahydrocannabinol (Delta-8 THC), an isomer of Delta-9 THC has recently surged. While Delta-8 THC has psychoactive effects and is potentially harmful, little is known about its use. We examined sociodemographic characteristics, motivations, and consumption patterns of Delta-8 THC in US adult cannabis users.
METHODS: Cannabis-using adult online survey participants (N = 4,348) provided information on Delta-8 use, and other characteristics. We assessed frequencies of sociodemographics, patterns, and correlates of Delta-8 THC use. Regression models estimated adjusted odds ratios (aOR) and 95% confidence intervals (CI) of associations between past 30-day Delta-8 THC use, sociodemographic and other characteristics.
FINDINGS: Among past 30-day cannabis users, 16.7% reported Delta-8 THC use. The most common consumption method was vaping concentrated formulations of Delta-8 THC (41.2%). Primary motivations for use were its legal status and perceived therapeutic benefits. Males were more likely than females to report Delta-8 THC use (aOR = 1.4, 95% CI 1.2, 1.7). Respondents residing in states with restrictions on sales of Delta-8 THC products had lower odds of Delta-8 THC use (aOR = 0.7, 95% CI 0.57, 0.86).
CONCLUSIONS: Findings provide initial insight into the current state of Delta-8 THC use in the US. Given the limited knowledge on use of Delta-8 THC, and considering emergence of reports indicating its harmful effects, there is urgent need for nationally representative data to investigate correlates of Delta-8 THC use (e.g., effectiveness of state-specific restrictions on its products). Such information can guide public-health policy around Delta-8 THC use.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cannabis; Delta-8 THC; Hemp; Marijuana; Tetrahydrocannabinol; Weed

Mesh:

Substances:

Year:  2022        PMID: 35644057      PMCID: PMC9245337          DOI: 10.1016/j.addbeh.2022.107374

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   4.591


  7 in total

1.  Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration.

Authors:  L E Hollister; H K Gillespie
Journal:  Clin Pharmacol Ther       Date:  1973 May-Jun       Impact factor: 6.875

2.  Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws.

Authors:  Deborah S Hasin; Jacob Borodovsky; Dvora Shmulewitz; Claire Walsh; Ofir Livne; Cara A Struble; Efrat Aharonovich; David S Fink; Alan Budney
Journal:  Drug Alcohol Depend       Date:  2021-10-29       Impact factor: 4.492

3.  Δ8-THC: Legal Status, Widespread Availability, and Safety Concerns.

Authors:  Shanna Babalonis; Wesley M Raup-Konsavage; Peter D Akpunonu; Agnes Balla; Kent E Vrana
Journal:  Cannabis Cannabinoid Res       Date:  2021-10

4.  The current state of delta-8 THC.

Authors:  Kelly Johnson-Arbor; Susan Smolinske
Journal:  Am J Emerg Med       Date:  2021-07-02       Impact factor: 4.093

Review 5.  The Use of Social Media in Recruitment for Medical Research Studies: A Scoping Review.

Authors:  Jane Topolovec-Vranic; Karthik Natarajan
Journal:  J Med Internet Res       Date:  2016-11-07       Impact factor: 5.428

Review 6.  The Use of Facebook in Recruiting Participants for Health Research Purposes: A Systematic Review.

Authors:  Christopher Whitaker; Sharon Stevelink; Nicola Fear
Journal:  J Med Internet Res       Date:  2017-08-28       Impact factor: 5.428

7.  Studying Cannabis Use Behaviors With Facebook and Web Surveys: Methods and Insights.

Authors:  Jacob T Borodovsky; Lisa A Marsch; Alan J Budney
Journal:  JMIR Public Health Surveill       Date:  2018-05-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.